Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

IONS(unaudited, in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecemberDecember2012201120122011Revenue, net  Esbriet

$

8,222$

2,660$

26,174$

2,778  Collaboration revenue-0-2,629Total revenue, net8,2222,66026,1745,407Costs and expenses:  Cost of goods sold2,7161,0218,9161,406  Research and development32,01821,006106,57174,973  Selling, general and administrative29,61526,802105,29589,463Total costs and expenses64,34948,829220,782165,842Loss from operations(56,127)(46,169)(194,608)(160,435)Interest income134166586556Interest expense(2,454)(2,254)(8,927)(6,408)Other income (expense)(224)(336)(373)(658)Loss from operations before income taxes(58,671)(48,593)(203,322)(166,945)Income tax expense (benefit)626(1,579)(19,230)(4,760)Loss from continuing operations (59,297)(47,014)(184,092)(162,185)Income (loss) from discontinued operations, net of taxes7332,48134,0117,411Net loss

$

(58,564)$

(44,533)$

(150,081)$

(154,774)Basic and diluted net income (loss) per common share:Continuing operations(0.91)(0.73)(2.82)(2.70)Discontinued operations0.010.040.520.12$

(0.90)$

(0.69)$

(2.30)$

(2.58)Shares used in computing basic and diluted net loss per share65,40464,57265,18460,100 

 InterMune, Inc.PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS(unaudited, in thousands)DecemberDecember 31,20122011Cash, cash equivalents and available-for-sale securities

$

307,986$

425,110Acquired product rights, net18,25019,250Other assets37,23028,263  Total assets

$

363,466$

472,623Total other liabilities

$

56,899$

34,205Convertible notes240,250240,250Stockholders' equity66,317198,168  Total liabilities and stockholders' equity

$

363,466$

472,623


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... a maker of cardiology information and imaging systems, ... Birmingham, Alabama, for $40 million in cash. , ,Emageon ... gives each company an entre into the other's market, ... in Madison and an Emageon board member. , ...
... a developer of a new platform technology using liquid ... monitoring, raised $1.2 million in its most recent round ... , ,Platypus qualified under Wisconsin Act 255, which grants ... up companies. The company is located in the New ...
... - Last week Gov. Jim Doyle announced a new eHealth ... further the adoption of electronic medical records in Wisconsin. , ... of information technology at the most important point in the ... statement, citing statistics showing 30 percent of healthcare costs are ...
Cached Biology Technology:Camtronics Medical Systems is bought by Alabama company 2Wisconsin pushes for adoption of electronic health records 2
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... for prostate cancer that measures minute fragments of RNA ... University of Michigan MLabs. The new testMi-Prostate Score (MiPS)improves ... ability to pick out high-risk prostate tumors from low-risk ... of men avoid unnecessary biopsies. The MiPS test ...
... joined the European Union on 1 July and conservation scientists fear ... population. The country has been managing its brown bears as ... bears are a protected species and can only be shot if ... seem to be a positive outcome for the bears. However, it ...
... the human body, particularly neuroproteins that maintain proper brain ... and Parkinson,s are known as "tangle diseases" because they ... in the brain. A team of Australian and ... BMAA can be inserted into neuroproteins, causing them to ...
Cached Biology News:Prostate Cancer Foundation announces new urine test for prostate cancer available 2Prostate Cancer Foundation announces new urine test for prostate cancer available 3European law could be unbearable for Croatia's brown bears 2Jackson Hole, Wyoming: New mechanism for protein misfolding may link to ALS 2
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Biology Products: